Materials. Commercial grade reagents and solvents were used as purchased without additional purification. NMR solvents CDCl3, dimethylsulfoxide-d6, acetone-d6 and D2O (100% d, ampules), were purchased from Cambridge Isotope Laboratories, Inc. All other reagents and solvents were purchased from commercial suppliers.
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Synthetic Procedures
Scheme S1. Synthesis of the cavitand 1 and the cavitand 2.
Synthesis of the cavitand 1.
Compound b.
To an ice-cold solution of nitrobenzoyl chloride (0.629 g, 3.39 mmol, 8.2 equiv) in AcOEt (80 mL) were added compound a (2) (0.6 g, 0.41 mmol, 1 equiv) and slowly an aqueous solution (80 mL) of K2CO3 (20 g). The mixture was degassed by brief exposure to vacuum and stirred vigorously at room temperature for 3 days under a nitrogen atmosphere. After NaCl (12 g) was added to the yellow suspension. The organic layer was separated and allowed to stand at 4°C overnight. The suspended solid was collected by vacuum filtration and washed with H2O (2 x 10 mL), 0°C cold MeOH (3 x 10 mL), and Et2O (3 x 10 mL). After drying in vacuo compound b was obtained as light yellow flaky solid (0.67 g, 0.28 mmol, 67%) 1 Then the mixture was cooled to room temperature and kept under N2 atmosphere. Et2O (100mL) was added slowly through the septum whilst stirring fast. The resulting suspension was allowed to stand at to 0°C and the supernatant removed with a syringe. MeOH (80mL) was added and the suspension was heated up to 60°c and stirred until complete dissolution was achieved. The solution was concentrated at 60°c at rotavapor until the first solid appeared and slowly added to stirred, ice-cold Et2O (400mL). The mixture was stirred overnight. The precipitate was collected by centrifugation, washed with Et2O (3 x 40mL) and then dried under high-vacuum to give 1 as pale orange solid (0.136 g, 0.05 mmol, 75%). 1 
Synthesis of the cavitand 2.
Compound c. SnCl2 dihydrate (1,408 g, 6,24 mmol) was added to a 0°C cold suspension of compound b (0.1 g, 0.04 mmol) in EtOH (8 mL) and concentrated aqueous HCl (2 mL) was slowly added. The reaction mixture was degassed and set under a nitrogen atmosphere. The mixture was heated to 110 °C for 1 h and then cooled to room temperature. EtOH was evaporated and ice-cold 3N aqueous HCl (30 mL) was added. After filtration, the solid obtained was washed with 0°C cold MeCN (3 X 5mL), Et2O (3 X 10mL) and dried under vacuum, yielding compound c (102 mg, 0.04 mmol, quant) as hydrochloride that was taken directly to the next step. Cavitand 2. The solution of c (0.12 g, 0.049 mmol) in 1-methylimidazole (12.1 mL) was heated at 90°C for 14 h under a nitrogen atmosphere, then the mixture was cooled to room temperature. The resulting suspension was taken into a syringe and added dropwise to 0°C Et2O (100mL) stirred under a nitrogen atmosphere. The precipitate was collected by centrifugation and washed with Et2O (3 x 40mL) and then MeCN (2 x 25 mL). The residue was dissolved with 60°C hot H2O (20mL) and after lyophilization the cavitand 2 was obtained as a pale ocher solid (0.104 g, 0.042 mmol, 86%). 1 vase conformation in aqueous solutions and broadened aryl C−H signals between 6.0 and 6.5 ppm are not observed even in absence of hydrophobic guests. The characteristic methine peak is marked with a blue dot. Figure S5 . 1 H NMR [600 MHz, D2O/DMSO-d6 95:5 (vol/vol), 298 K] spectrum of the complexes of 1 (1.0 mM) with hexadecane (C16). The pronounced peak splitting of upfield signals for the bound long alkane guests is extended to the host structure, and the aromatic region in particular. The cavitand 1 exists in different isomeric forms that interconvert slowly on the NMR timescale; the guests in inverted J-shaped conformations can produce hydrophobic interactions with the "prestacked" aromatic system and stabilize the complex. This can reduce the number of conformers. 
